Hot Investor Mandate 3: Canada-Based Investment Group Provides Seed Funding to Medtech, Cleantech, and IT Sectors Across North America, With Canadian Focus

22 Mar

A venture capital fund, angel group, and registered exempt market dealer based in Toronto, Ontario is affiliated with early stage venture funds, including their accelerator fund I and II as well as an angel group. The firm usually acts a lead investor in rounds of up to $2M, with between $300K – $750K coming from the first-mentioned fund, and with additional capital usually coming from the angel group or other family offices or institutional investment partners. The firm has also participated, and will continue to participate, in larger syndicated investment rounds. The firm prefers to lead priced equity rounds and does not usually make investments in uncapped convertible debt or SAFEs (Simple Agreements for Future Equity).

Annually, the firm works with, and makes investments in, 8 to 12 early stage (Seed and Series A) companies in the IT, CleanTech and MedTech sectors. In the MedTech sector, the firm typically does not invest in products with a complex regulatory pathway. The firm is also interested in platform technologies and R&D service/tools companies. Historic MedTech investments include investments in (i) a company which has developed an imaging agent that illuminates tumors both at the surgery planning phase and inside the operating room, (ii) a company that manufactures the world’s only natural, non-toxic, mono-disperse nano particle extracted from sweet corn which has applications in the personal care/cosmetics, nutraceutical and biomedical spaces; and (iii) a company that has a proprietary in silico software platform that maps interactions of drug compounds against the human proteome to identify drug efficacy, side effects and toxicity risks.

The firm is focused on Canadian companies, but will also evaluate U.S.-based and international companies if there is a potential investment fit. The firm’s principals have significant technology, financial and legal experience. The firm’s ideal investment candidate is a company that will benefit from and can leverage this experience and network and to which the firm can provide additional long-term value beyond its cash investment. The firm tries to avoid taking on technology risk but will take on some commercialization risk and prefers entrepreneurs that have had at least one ‘win’ (or event better, at least one ‘loss’)

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: